Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3
Molecular Pharmacology · 2024-04 · 105 (4) · 301-312
DOI: 10.1124/molpharm.123.000835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmacology, 2024-04. Verfasst von Aurelien M Zarca und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry (A.M.Z., M.A.-S., I.A.S., J.P.B., H.G.J.C., K.L.V., M.C.M.L.B., D.N.N., R.B., I.J.P.dE., H.F.V., M.W., C.dG., B.A.Z…. Hauptthemen laut MEDLINE: Receptors, CXCR4, Chemokine CXCL12. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Atypical chemokine receptor 3 (ACKR3), formerly referred to as CXCR7, is considered to be an interesting drug target. In this study, we report on the synthesis, pharmacological characterization and radiolabeling of VUF15485, a new ACKR3 small-molecule agonist, that will serve as an important new tool to study this β-arrestin-biased chemokine receptor. VUF15485 binds with nanomolar affinity (pIC50 = 8.3) to human ACKR3, as measured in [125I]CXCL12 competition binding experiments. Moreover, in a bioluminescence resonance energy transfer-based β-arrestin2 recruitment assay VUF15485 acts as a potent ACKR3 agonist (pEC50 = 7.6) and shows a similar extent of receptor activation compared with CXCL12 when using a newly developed, fluorescence resonance energy transfer-based ACKR3 conformational sensor. Moreover, the ACKR3 agonist VUF15485, tested against a (atypical) chemokine receptor panel (agonist and antagonist mode), proves to be selective for ACKR3. VUF15485 labeled with tritium at one of its methoxy groups ([3H]VUF15485), binds ACKR3 saturably and with high affinity (K d = 8.2 nM). Additionally, [3H]VUF15485 shows rapid binding kinetics and consequently a short residence time (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry (A.M.Z., M.A.-S., I.A.S., J.P.B., H.G.J.C., K.L.V., M.C.M.L.B., D.N.N., R.B., I.J.P.dE., H.F.V., M.W., C.dG., B.A.Z., M.J.S., R.L.) and Department of Chemistry & Pharmaceutical Sciences…
ORCID-Profile: Martyna Szpakowska, Carsten Hoffmann, Martine J Smit, Rob Leurs
Zitieren
APA
Zarca, A. M., Adlere, I., Viciano, C. P., Arimont-Segura, M., Meyrath, M., Simon, I. A., Bebelman, J. P., Laan, D., Custers, H. G. J., Janssen, E., Versteegh, K. L., Buzink, M. C. M. L., Nesheva, D. N., Bosma, R., de Esch, I. J. P., Vischer, H. F., Wijtmans, M., Szpakowska, M., Chevigné, A., …, & Leurs, R. (2024). Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3. Molecular Pharmacology, 105(4), 301-312. https://doi.org/10.1124/molpharm.123.000835
Vancouver
Zarca AM, Adlere I, Viciano CP, Arimont-Segura M, Meyrath M, Simon IA, et al. Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3. Molecular Pharmacology. 2024;105(4):301-312. doi:10.1124/molpharm.123.000835
BibTeX
@article{Zarca2024,
author = {Zarca, Aurelien M and Adlere, Ilze and Viciano, Cristina P and Arimont-Segura, Marta and Meyrath, Max and Simon, Icaro A and Bebelman, Jan Paul and Laan, Dennis and Custers, Hans G J and Janssen, Elwin and Versteegh, Kobus L and Buzink, Maurice C M L and Nesheva, Desislava N and Bosma, Reggie and de Esch, Iwan J P and Vischer, Henry F and Wijtmans, Maikel and Szpakowska, Martyna and Chevigné, Andy and Hoffmann, Carsten and de Graaf, Chris and Zarzycka, Barbara A and Windhorst, Albert D and Smit, Martine J and Leurs, Rob},
title = {Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3},
journal = {Molecular Pharmacology},
year = {2024},
volume = {105},
number = {4},
pages = {301--312},
doi = {10.1124/molpharm.123.000835}
}
EUVIMED